These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1925 related articles for article (PubMed ID: 33734021)

  • 1. Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.
    Copertino DC; Casado Lima BC; Duarte RRR; Powell TR; Ormsby CE; Wilkin T; Gulick RM; de Mulder Rougvie M; Nixon DF
    J Biomol Struct Dyn; 2022 Oct; 40(16):7367-7380. PubMed ID: 33734021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretrovirals for Prophylaxis Against COVID-19: A Comprehensive Literature Review.
    Alavian G; Kolahdouzan K; Mortezazadeh M; Torabi ZS
    J Clin Pharmacol; 2021 May; 61(5):581-590. PubMed ID: 33217030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?
    Dallocchio RN; Dessì A; De Vito A; Delogu G; Serra PA; Madeddu G
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2435-2448. PubMed ID: 33755983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
    Fintelman-Rodrigues N; Sacramento CQ; Ribeiro Lima C; Souza da Silva F; Ferreira AC; Mattos M; de Freitas CS; Cardoso Soares V; da Silva Gomes Dias S; Temerozo JR; Miranda MD; Matos AR; Bozza FA; Carels N; Alves CR; Siqueira MM; Bozza PT; Souza TML
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32759267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19.
    Rafi MO; Bhattacharje G; Al-Khafaji K; Taskin-Tok T; Alfasane MA; Das AK; Parvez MAK; Rahman MS
    J Biomol Struct Dyn; 2022 May; 40(8):3711-3730. PubMed ID: 33251975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro.
    Zhang L; Liu J; Cao R; Xu M; Wu Y; Shang W; Wang X; Zhang H; Jiang X; Sun Y; Hu H; Li Y; Zou G; Zhang M; Zhao L; Li W; Guo X; Zhuang X; Yang XL; Shi ZL; Deng F; Hu Z; Xiao G; Wang M; Zhong W
    Virol Sin; 2020 Dec; 35(6):776-784. PubMed ID: 32910347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
    Choudhury M; Dhanabalan AK; Goswami N
    J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.
    Magro P; Zanella I; Pescarolo M; Castelli F; Quiros-Roldan E
    Biomed J; 2021 Mar; 44(1):43-53. PubMed ID: 33608241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
    Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
    J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.
    Feng JY; Du Pont V; Babusis D; Gordon CJ; Tchesnokov EP; Perry JK; Duong V; Vijjapurapu A; Zhao X; Chan J; Cohen C; Juneja K; Cihlar T; Götte M; Bilello JP
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
    Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
    Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.
    Pauly I; Kumar Singh A; Kumar A; Singh Y; Thareja S; Kamal MA; Verma A; Kumar P
    Curr Pharm Des; 2022; 28(46):3677-3705. PubMed ID: 36345244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repositioning Therapeutics for SARS-CoV-2: Virtual Screening of Plant-based Anti-HIV Compounds as Possible Inhibitors against COVID-19 Viral RdRp.
    Murali M; Gowtham HG; Ansari MA; Alomary MN; Alghamdi S; Almehmadi M; Singh SB; Shilpa N; Aiyaz M; Kalegowda N; Ledesma AE; Amruthesh KN
    Curr Pharm Des; 2022; 28(12):969-980. PubMed ID: 35796443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparative Study of Antiretroviral (Lopinavir/Ritonavir) and Remdesivir Used in the Pandemic in Iraq on the Clinical Outcome in Patients with SARS-CoV-2.
    Alabdalaali MM; Hadi AM
    Arch Razi Inst; 2023 Jun; 78(3):935-941. PubMed ID: 38028857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19.
    von Hentig N
    Eur J Clin Pharmacol; 2021 Sep; 77(9):1297-1307. PubMed ID: 33660020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2
    Singh S; Sk MF; Sonawane A; Kar P; Sadhukhan S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6249-6264. PubMed ID: 32720577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 97.